Head-to-head · 2026
SemaglutidevsTirzepatide
Compared through their weight-loss brands: semaglutide is sold as Wegovy, tirzepatide as Zepbound.
Wegovy
Semaglutide
vs
Zepbound
Tirzepatide
The short answer
Zepbound edges out Wegovy in our scoring, 8.5/10 versus 8.4/10. Zepbound (Tirzepatide) and Wegovy (Semaglutide) are both GLP-1 receptor agonists; the gap comes from differences in efficacy data, cost, and access. Neither is universally better — the right choice depends on your insurance, diagnosis, and tolerance.
The key difference
Semaglutide vs Tirzepatide: what actually differs
Semaglutide (sold as Wegovy) and tirzepatide (sold as Zepbound) are both weekly GLP-1 injections for weight loss, but they are different molecules: semaglutide is a single GLP-1 agonist, while tirzepatide is a dual GIP/GLP-1 agonist. In the head-to-head SURMOUNT-5 trial, tirzepatide produced greater average weight loss — 20.2% vs 13.7% at 72 weeks.
Boxed warning (class-wide for GLP-1s): risk of thyroid C-cell tumors. Contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
| Attribute | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist FDA label | Dual GIP/GLP-1 receptor agonist FDA label |
| Head-to-head weight loss (72 wk) | 13.7 % | 20.2 % |
| Weight-loss brand | Wegovy Novo Nordisk | Zepbound Eli Lilly |
| Max dose (weekly SC) | 2.4 mg Wegovy FDA label (HD 7.2 mg, Mar 2026) | 15 mg Zepbound FDA label |
| FDA indication | Chronic weight management FDA label | Chronic weight management + OSA FDA label |
| Retail cash price | $1,349/mo Retail cash (Wegovy) | $1,349/mo Retail cash (Zepbound) |
| Manufacturer cash-pay | 499 $/mo NovoCare (Wegovy) | 549 $/mo LillyDirect (Zepbound) |
| Rx status | Rx only FDA | Rx only FDA |
Side effects compared — incidence
| Effect | Semaglutide | Tirzepatide |
|---|---|---|
| Nausea | 44% | 29% |
| Vomiting | 24% | 13% |
| Diarrhea | 30% | 23% |
| Constipation | 24% | 17% |
FDA prescribing-info baselines. Lower is better (green).
Choose Semaglutide if
- You want the lower manufacturer cash-pay price — Wegovy is $499/mo via NovoCare vs $549/mo for Zepbound via LillyDirect (retail is the same $1,349/mo for both).
- You prefer the longer track record — semaglutide (Wegovy) has been FDA-approved for weight management since 2021, roughly two years ahead of tirzepatide.
- You have established cardiovascular disease without diabetes — Wegovy carries the SELECT label (20% MACE reduction) that Zepbound does not.
Choose Tirzepatide if
- Your priority is maximum weight loss — in the head-to-head SURMOUNT-5 trial tirzepatide beat semaglutide, 20.2% vs 13.7% mean loss at 72 weeks.
- You want fewer GI side effects — Zepbound ran lower nausea (29% vs 44%), vomiting (13% vs 24%), and diarrhea (23% vs 30%) than Wegovy in FDA prescribing data.
- You also have obstructive sleep apnea — tirzepatide (Zepbound) carries an FDA OSA indication that semaglutide does not.
Switching between Semaglutide & Tirzepatide
Switching between semaglutide and tirzepatide is a change of molecule, not a dose conversion — a prescriber restarts titration at the new drug’s starting dose (Wegovy 0.25 mg or Zepbound 2.5 mg weekly) and steps up over weeks to manage GI tolerance. People most often switch from semaglutide to tirzepatide for greater weight loss; the reverse is usually for cost, a cardiovascular indication, or GI tolerability.
Independently sourced from the cited trials; last verified July 2026. Editorial summary, not medical advice — see our methodology and editorial standards.
The verdict
Why Zepbound ranks first
Zepbound scores 8.5/10 vs Wegovy at 8.4/10. Detailed breakdown below.
- Top pick1Editor's Choice
FDA-approved tirzepatide for weight loss
- Highest reported weight loss of any approved GLP-1 (avg ~21% in SURMOUNT-1)
- Dual GIP + GLP-1 mechanism
- FDA-approved for OSA + obesity (2024)
FDA-approvedBrand-nameOnce-weekly injectionDual GIP / GLP-1Insurance eligible8.5/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there.See reviewTrue cost · maint.$549/mo · 10mg+$150 - 2Best for editor's choice#1· Editor's ChoiceEditor's ChoiceBest for CV Risk
FDA-approved semaglutide for chronic weight management
- Average 15% weight loss in clinical trials (STEP 1)
- FDA-approved with extensive safety record
- Weekly dosing
FDA-approvedBrand-nameOnce-weekly injectionGLP-1 receptor agonistInsurance eligibleMost transparent pricing8.4/10Editorial scoreiEditorial score — our drug ranking, weighted for clinical outcome (effectiveness and safety lead). Telehealth services also carry a separate Service scorecard (shown on the services pages), so the same brand can show a different number there.See reviewTrue cost · maint.$499/mo · 2.4mg
Winners per category
Editorial pick
Zepbound
Highest combined score across six axes. FDA-approved tirzepatide for weight loss
8.5
/10
- Most effectiveZepboundScore: 9.8/10
- Best valueZepboundScore: 5.5/10
- Safest profileZepboundScore: 8.5/10
- Easiest accessZepboundScore: 6.5/10
- Most trustedWegovyScore: 9.5/10
Score comparison
Side-by-side scoring breakdown
ZepboundWegovy
Effectiveness
0 — 10
Zepbound
9.8
Wegovy
9.5
Safety
0 — 10
Zepbound
8.5
Wegovy
8.5
Value
0 — 10
Zepbound
5.5
Wegovy
5.0
Accessibility
0 — 10
Zepbound
6.5
Wegovy
6.0
User experience
0 — 10
Zepbound
7.5
Wegovy
7.5
Trust
0 — 10
Zepbound
9.0
Wegovy
9.5
Side-by-side specs
| # | Product | Active ingredient | Starting price | True cost · maint. | FDA status | Score | |
|---|---|---|---|---|---|---|---|
| 1 | Zepbound | Tirzepatide | Best ·$1349/mo | $549/mo · 10mg+$150 | approved | Top ·8.5 | View → |
| 2 | Wegovy Most transparent pricing | Semaglutide | Best ·$1349/mo | Best ·$499/mo · 2.4mg | approved | 8.4 | View → |
Effectiveness: Zepbound vs Wegovy
Zepbound (Tirzepatide) and Wegovy (Semaglutide) both belong to the GLP-1 receptor agonist class, but their molecular structure and dosing differ enough to produce different real-world outcomes. Head-to-head trial data is limited; most comparisons come from cross-trial analysis of pivotal studies (STEP-1, SURMOUNT-1, SELECT, SUSTAIN).
On weight loss, Zepbound typically shows stronger placebo-adjusted reductions at 68 weeks, with greater proportions of patients reaching ≥15% body-weight loss. For type 2 diabetes patients, A1C reduction tends to track with the drug's underlying glucose-handling mechanism — single-agonist semaglutide compounds (Wegovy, Ozempic, Rybelsus) yield ~1.5% A1C drop, while dual GIP/GLP-1 agonists (Mounjaro, Zepbound) frequently exceed 2.0%.
Tolerability
Side effects: what to expect
GI side effects dominate the first 8-12 weeks of GLP-1 therapy regardless of which drug you start on. Nausea (35-45%), diarrhea (15-25%), constipation (15-20%), vomiting (10-15%), and headache (10-15%) are the most reported. Zepbound and Wegovy share this profile; the difference is usually in titration aggressiveness and individual tolerance, not the drug itself.
More serious but rare adverse events — pancreatitis, gallbladder disease, kidney injury during dehydration, and the boxed warning for medullary thyroid cancer in rodent models — apply to the entire GLP-1 class. If you have a personal or family history of MTC or MEN2, neither Zepbound nor Wegovy is appropriate. Talk to your prescribing physician about your risk profile before starting either.
Cost & access
Cost & insurance
Without insurance coverage, both Zepbound and Wegovy run between $1,000 and $1,400 per month at list price. Coverage decisions hinge on whether your plan treats the drug as a weight-loss medication (often excluded from formulary) or a diabetes medication (typically covered). Medicare Part D specifically excludes weight-loss indications under current rules, so a Wegovy prescription is denied even though Ozempic (same molecule) is covered for T2D — a gap that drives many switching decisions.
Manufacturer savings cards can lower out-of-pocket cost to as little as $25-$650/month for commercially insured patients depending on plan tier. If you're uninsured or your plan rejects coverage, compounded semaglutide and tirzepatide from licensed 503A/503B pharmacies are typically 60-80% cheaper but carry quality-variability and supply-chain risks that brand drugs don't.
Who it's for
Which one fits you
Who should choose Zepbound?
- You prioritize the strongest available weight-loss data and your insurance covers it, or you're willing to pay out of pocket via savings card.
- You have a cardiovascular risk profile that benefits from the trial evidence supporting this drug's class indication.
- Your prescriber is familiar with the titration schedule and your plan's prior authorization workflow.
Who should choose Wegovy?
- You prefer the alternative active ingredient based on tolerability, availability in your area, or insurance coverage.
- You had difficulty with prior Zepbound side effects and want to try a different molecule.
- Your prescribing clinic stocks it, has experience with its titration, or your pharmacy shows lower wait times.
If you're already on one
Switching between them
Switching from Zepbound to Wegovy (or vice versa) is generally straightforward but requires a careful titration restart, not a direct dose swap. Your prescriber will typically pause for 1 week, then begin the new drug at its lowest dose regardless of where you were on the original. This minimizes GI side effects from a full-strength reintroduction. Expect 4-12 weeks before reaching the maintenance dose on the new medication.
Reasons people switch include: insurance formulary changes, shortage of the original drug, intolerable side effects, plateauing weight loss, or moving from a single-agonist to a dual-agonist compound. The choice should always go through your prescribing physician — do not self-switch using compounded products without medical supervision.
Bottom line
Zepbound is our pick — but the deciding factor is yours
Zepbound is our editorial pick in this matchup with an overall score of 8.5/10, edging out Wegovy at 8.4/10. The score reflects a weighted average of clinical efficacy, safety profile, cost transparency, and access — not just trial outcomes. For most patients comparing these two, insurance coverage and pharmacy access will outweigh the scoring differential. Verify both with your prescriber and plan before committing.
From the brief
Recent editorial coverage
May 12, 2026· #018
TrumpRx adds Lilly. Zepbound now $549 direct.
Eli Lilly joins TrumpRx with Zepbound + Mounjaro at $549/mo cash. Plus: FDA Q1 enforcement actions, Hims settlement aftermath, and three new compounders we are watching.
Read issue →May 5, 2026· #017
FDA declares Wegovy shortage officially over.
The 28-month Wegovy shortage ended this week. Compounders now face 60-day wind-down. What this means for the ~1.2M patients on compounded semaglutide — and your prescription path forward.
Read issue →Apr 28, 2026· #016
CMS finalizes Wegovy obesity coverage. PA still required.
Medicare Part D will cover Wegovy for obesity starting July 1, 2026 — but with strict prior auth. We obtained the draft PA criteria and cross-checked every line against the published rule.
Read issue →